Focus on Pathways: Targeting the CSF-1R Pathway in Graft-vs-Host Disease - Episode 3

AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

EP. 1: Graft-Versus-Host Disease: Pathogenesis, Clinical Challenges, and Unmet Treatment Needs
EP. 2: The CSF-1R Signaling Pathway in GVHD and Investigational Agents Targeting this Pathway
Now Viewing
EP. 3: AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD
EP. 4: Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD

Related Content:

Focus on Pathways: Targeting the CSF-1R Pathway in Graft-vs-Host DiseaseThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)Hematologic Oncology
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation